Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Glomerulonephritis: Current Diagnosis, Treatment and Future Options
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Glomerulonephritis: Current Diagnosis, Treatment and Future Options

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: 25 November 2025 | Viewed by 7903

Special Issue Editors

Dr. Ana I. Ávila

E-Mail Website
Guest Editor
1. Hospital Universitario Doctor Peset, 46017 Valencia, Spain
2. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 46020 Valencia, Spain
3. Department of Medicine, University of Valencia, 46010 Valencia, Spain
Interests: glomerulonephritis; kidney transplant; nephrology; medicine
Dr. Montserrat M. Díaz-Encarnación

E-Mail Website
Guest Editor
Fundacio Puigvert Universitary Hospital, Autonomus of Barcelona University, 08025 Barcelona, Spain
Interests: autoimmune diseases with kidney involvement; glomerulonephritis; acute interstitial nephritis; renal involvement in hematological and oncological diseases

Special Issue Information

Dear Colleagues,

Glomerulonephritis is a complex and challenging condition affecting the kidneys, being the cause of ESRD in up to 30% of patients reaching RRT and causing an enormous impact on patients and a burden for the health system.

This Special Issue aims to explore the significant advancements in the diagnosis and management of distinct glomerulonephritis made in recent years.

The topics of interest for publication include, but are not limited to, the latest diagnostic techniques used to identify glomerulonephritis. Additionally, we are interested in hearing about the various treatment options available for patients with glomerulonephritis. Furthermore, we are excited to learn about any promising future treatments or research developments in the field of glomerulonephritis. This could include novel drug therapies, emerging technologies, or potential genetic factors influencing the disease.

For this Special Issue, original research articles and reviews are welcome.

Your contribution to this Special Issue will not only educate our readers but also help advance our understanding of glomerulonephritis and improve patient outcomes. We look forward to receiving your contributions on this important subject.

Dr. Ana I. Ávila
Dr. Montserrat M. Díaz-Encarnación
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glomerulonephritis
  • diagnosis
  • management
  • drug therapies
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 5928 KiB  
Article
The Influence of Anti-ETAR and Anti-CXCR3 Antibody Levels on the Course of Specific Glomerulonephritis Types
by Maciej Szymczak, Harald Heidecke, Marcelina Żabińska, Łucja Janek, Jakub Wronowicz, Krzysztof Kujawa, Karolina Bukowiec-Marek, Tomasz Gołębiowski, Karolina Skalec, Kai Schulze-Forster, Andrzej Konieczny and Mirosław Banasik
J. Clin. Med. 2024, 13(24), 7752; https://doi.org/10.3390/jcm13247752 - 19 Dec 2024
Cited by 1 | Viewed by 983
Abstract
Background: Anti-ETAR (endothelin A receptor) antibodies and anti-CXCR3 (C-X-C motif chemokine receptor 3) antibodies are types of non-HLA (human leukocyte antigens) antibodies that could have some influence on the course of glomerulonephritis. The authors aimed to study the influence of these antibodies’ levels [...] Read more.
Background: Anti-ETAR (endothelin A receptor) antibodies and anti-CXCR3 (C-X-C motif chemokine receptor 3) antibodies are types of non-HLA (human leukocyte antigens) antibodies that could have some influence on the course of glomerulonephritis. The authors aimed to study the influence of these antibodies’ levels on the course of specific glomerulonephritis types. Methods: We evaluated the anti-ETAR and anti-CXCR3 antibody levels in the serum of patients with membranous nephropathy (n = 18), focal and segmental glomerulosclerosis (FSGS) (n = 25), systemic lupus erythematosus (n = 17), IgA nephropathy (n = 14), mesangiocapillary glomerulonephritis (n = 6), anti-neutrophil cytoplasmic antibodies (c-ANCA) vasculitis (n = 40), and perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) vasculitis (n = 16), and we compared their levels with the control group (n = 22). Next, we observed the patients’ clinical parameters (serum creatinine, albumin, total protein) for 2 years and checked the correlation of the clinical course markers with basic receptor antibody level. Results: Our results indicate lower anti-ETAR antibody levels in patients with FSGS and IgA nephropathy compared to the control group. Both types of antibodies correlated with creatinine levels after 2 years of observation in IgA nephropathy. Both types of antibodies seemed to negatively influence the total protein and albumin levels in systemic lupus erythematosus. Conclusions: This prospective observation showed that anti-ETAR and anti-CXCR 3 antibody levels are connected with the course of IgA nephropathy and lupus nephritis. Full article
(This article belongs to the Special Issue Glomerulonephritis: Current Diagnosis, Treatment and Future Options)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 3272 KiB  
Review
Diagnosis and Treatment of Renal ANCA Vasculitis: A Summary of the Consensus Document of the Catalan Group for the Study of Glomerular Diseases (GLOMCAT)
by Juliana Bordignon Draibe, Helena Marco, Meritxell Ibernon, Irene Agraz, Carola Arcal, Xoana Barros, Victoria Cabrera, Iara Da Silva, Montserrat Díaz, Xavier Fulladosa, Elena Guillén, Patricia Lescano, Laura Martínez Valenzuela, Eva Márquez, Nadia Martín, Ana Merino, Maru Navarro, Eva Rodríguez, Mª José Soler, Joan Torras, Luís F. Quintana and on behalf of the Catalan Society of Nephrologyadd Show full author list remove Hide full author list
J. Clin. Med. 2024, 13(22), 6793; https://doi.org/10.3390/jcm13226793 - 12 Nov 2024
Viewed by 2666
Abstract
The document provides a comprehensive overview of the diagnosis, monitoring, and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) with renal involvement, focusing on granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). It outlines the definitions, clinical presentation, histopathological classification, monitoring strategies, induction and [...] Read more.
The document provides a comprehensive overview of the diagnosis, monitoring, and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) with renal involvement, focusing on granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). It outlines the definitions, clinical presentation, histopathological classification, monitoring strategies, induction and maintenance treatments, as well as special considerations for relapsing, refractory, and frail patients with renal AAV. The document was prepared by the Catalan Group for the Study of Glomerular Diseases (GLOMCAT), which comprises nephrologists with extensive experience in the diagnosis and treatment of AAV patients. Several virtual and face-to-face meetings were held for coordination, section assignments, and content discussion. An exhaustive and systematic search of the literature was carried out, which included, among others, the following databases: PubMed, EMBASE, Cochrane Library, Google Scholar, and ClinicalTrials.gov, as well as the abstract books of national and international congresses. Overall, the document provides a comprehensive guide for clinicians managing patients with renal AAV, offering evidence-based recommendations for diagnosis, monitoring, and treatment across various clinical scenarios. Full article
(This article belongs to the Special Issue Glomerulonephritis: Current Diagnosis, Treatment and Future Options)
►▼ Show Figures

Figure 1

12 pages, 1393 KiB  
Review
Role of Avacopan on Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
by Justo Sandino and Enrique Morales
J. Clin. Med. 2024, 13(22), 6676; https://doi.org/10.3390/jcm13226676 - 7 Nov 2024
Cited by 1 | Viewed by 3596
Abstract
Antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis are a group of autoimmune diseases characterized by inflammation of the microvasculature, leading to life-threatening complications, including kidney disease. These diseases are associated with a high morbidity and mortality rate. Conventional treatment modalities have evolved towards personalized therapies [...] Read more.
Antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis are a group of autoimmune diseases characterized by inflammation of the microvasculature, leading to life-threatening complications, including kidney disease. These diseases are associated with a high morbidity and mortality rate. Conventional treatment modalities have evolved towards personalized therapies intending to mitigate inflammation and minimize the adverse effects of traditional immunosuppressive agents. Avacopan, a novel C5a receptor inhibitor, represents a promising therapeutic option for vasculitis with renal involvement. This article provides a comprehensive review of the role of complement in the pathogenesis of vasculitis with renal involvement and the role of avacopan for its treatment, taking into account recent updates to both the EULAR and KDIGO guidelines and published experience of avacopan use in real clinical settings. Full article
(This article belongs to the Special Issue Glomerulonephritis: Current Diagnosis, Treatment and Future Options)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop